05-530-I Sigma-AldrichAnti-Rad51 Antibody, clone 3C10
This Anti-Rad51 Antibody, clone 3C10 is validated for use in Western Blotting, Immunoprecipitation for the detection of Rad51 .
More>> This Anti-Rad51 Antibody, clone 3C10 is validated for use in Western Blotting, Immunoprecipitation for the detection of Rad51 . Less<<Productos recomendados
Descripción
Replacement Information |
---|
Tabla espec. clave
Species Reactivity | Key Applications | Host | Format | Antibody Type |
---|---|---|---|---|
H | WB, IP | M | Purified | Monoclonal Antibody |
References |
---|
Product Information | |
---|---|
Format | Purified |
Presentation | Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. |
Quality Level | MQ100 |
Physicochemical Information |
---|
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Storage and Shipping Information | |
---|---|
Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. |
Packaging Information | |
---|---|
Material Size | 200 μg |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Número de referencia | GTIN |
05-530-I | 04055977173369 |
Documentation
Anti-Rad51 Antibody, clone 3C10 Ficha datos de seguridad (MSDS)
Título |
---|
Anti-Rad51 Antibody, clone 3C10 Certificados de análisis
Cargo | Número de lote |
---|---|
Anti-Rad51, clone 3C10 (mouse monoclonal) Monoclonal Antibody | Q2922327 |
Anti-Rad51, clone 3C10 - 3436195 | 3436195 |
Anti-Rad51, clone 3C10 - 3832627 | 3832627 |
Anti-Rad51, clone 3C10 - 3931783 | 3931783 |
Anti-Rad51, clone 3C10 - 4137149 | 4137149 |
Anti-Rad51, clone 3C10 - 4149123 | 4149123 |
Anti-Rad51, clone 3C10 -Q2574784 | Q2574784 |
Licencias necesarias e Información técnica
Cargo |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |